Our study demonstrates for the first that T-cell population characterization merely by surface chemokine receptor phenotyping is sufficient to provide a vital information concerning the likely outcome of patients that were treated with IL-17 targeted treatment, irrespectively whether that treatment relates to the inhibition of IL-17A or IL17-RA. The gene discussed is IL17A; the disease is rheumatoid arthritis.